Published in Cancer Weekly, November 26th, 2002
As revised, the company will sell at least $9.0 million common stock at $0.27 per share. All other terms of the financing remain unchanged. Investors in the transaction include Mi3 LP of Wellesley MA and Oxford Biosciences of Boston.
Photogen Technologies, Inc. is developing a platform of products with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.